Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
81 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Recruiting - Novartis Investigative Site
Herston, Queensland, Australia
Recruiting - Novartis Investigative Site
Melbourne, Victoria, Australia
Recruiting
- Novartis Investigative Site
São Paulo, São Paulo, Brazil
Recruiting - Novartis Investigative Site
São Paulo, São Paulo, Brazil
Recruiting
- Novartis Investigative Site
Fuzhou, Fujian, China
Recruiting - Novartis Investigative Site
Wuhan, Hubei, China
Recruiting - Novartis Investigative Site
Wuhan, Hubei, China
Recruiting - Novartis Investigative Site
Nanjing, Jiangsu, China
Recruiting - Novartis Investigative Site
Nanjing, Jiangsu, China
Recruiting - Novartis Investigative Site
Shenyang, Liaoning, China
Recruiting - Novartis Investigative Site
Xian, Shanxi, China
Recruiting - Novartis Investigative Site
Xian, Shanxi, China
Recruiting - Novartis Investigative Site
Chengdu, Sichuan, China
Recruiting - Novartis Investigative Site
Beijing, China
Recruiting - Novartis Investigative Site
Beijing, China
Recruiting - Novartis Investigative Site
Guangzhou, China
Recruiting - Novartis Investigative Site
Shanghai, China
Recruiting - Novartis Investigative Site
Shanghai, China
Recruiting - Novartis Investigative Site
Tianjin, China
Recruiting
- Novartis Investigative Site
Hong Kong, Hong Kong
Recruiting
- Novartis Investigative Site
Beersheba, Israel
Recruiting - Novartis Investigative Site
Haifa, Israel
Recruiting - Novartis Investigative Site
Jerusalem, Israel
Recruiting - Novartis Investigative Site
Petah Tikva, Israel
Recruiting - Novartis Investigative Site
Ramat Gan, Israel
Recruiting - Novartis Investigative Site
Tel Aviv, Israel
Recruiting
- Novartis Investigative Site
Kashiwa, Chiba, Japan
Recruiting - Novartis Investigative Site
Sapporo, Hokkaido, Japan
Recruiting - Novartis Investigative Site
Kobe, Hyōgo, Japan
Recruiting - Novartis Investigative Site
Yokohama, Kanagawa, Japan
Recruiting - Novartis Investigative Site
Chiba, Japan
Recruiting - Novartis Investigative Site
Fukuoka, Japan
Recruiting - Novartis Investigative Site
Fukuoka, Japan
Recruiting - Novartis Investigative Site
Fukuoka, Japan
Recruiting - Novartis Investigative Site
Fukushima, Japan
Recruiting - Novartis Investigative Site
Ishikawa, Japan
Recruiting - Novartis Investigative Site
Kyoto, Japan
Recruiting
- Novartis Investigative Site
Petaling Jaya, Selangor, Malaysia
Recruiting - Novartis Investigative Site
Petaling Jaya, Selangor, Malaysia
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Feb 2025
- Primary completion
- 27 Jun 2028
- Completion
- 19 Jul 2033
- Last update posted
- 27 May 2026
- Registered enrollment
- 443
- Registry id
- NCT06780670
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.